When should I pick SRT-2104 over Resveratrol?

Pick SRT-2104 if: - A research protocol requires direct, potent SIRT1 activation with documented lipid-lowering and anti-inflammatory effects - The goal is to drive mitochondrial biogenesis or PGC-1α/FOXO pathway modulation in a longevity or metabolic-health context - Stacking with NMN/NR and/or rapamycin for a high-impact, multi-mechanism longevity stack - Managing on-cycle dyslipidemia or chronic inflammation where robust, measurable effect is desired - Preference is for a compound with reproducible pharmacokinetics, clinical-phase data, and minimal CYP interactions Pick Resveratrol if: - Cost, safety, or ease of sourcing are top priorities for a stack - The protocol emphasizes cardiovascular support, mild antioxidant benefit, or broad-spectrum metabolic health - Looking for mild suppression of aromatase/estrogen signaling as an adjunct to TRT/AAS - Running a protocol where long-term t

Comparison

SRT-2104 vs Resveratrol

Q: SRT-2104 vs Resveratrol: which is better?

SRT-2104 wins for potent and direct SIRT1 activation, reliability of effect, improved pharmacokinetics, and evidence-backed impact on lipid profiles and inflammation in trials. Mechanistically, SRT-2104 actually activates SIRT1 (downstream of NMN/NR), offering precise, reproducible modulation with far higher bioavailability and selectivity than natural polyphenols. Resveratrol wins for safety, accessibility, cost, and established long-term tolerability. Its broader array of biological actions (SIRT1, AMPK, mild aromatase inhibition, antioxidant effect) makes it a well-rounded adjunct for stacked protocols. Sourcing is trivial, side effects are minimal, and it is routinely run at low cost across many stacks, though the effects are modest and bioavailability is a major limitation.

Direct SIRT1 activation versus broad, low-potency polyphenol effects.

SRT-2104

SIRT1 Activator (STAC)

Longevityt½ 15–20 hours

Resveratrol

Polyphenolic Stilbenoid / SIRT1 Activator

Longevityt½ 1–3 hours (parent); ~9 hours (total metabolites)

Effectiveness Profile

SRT-2104

Resveratrol

At a Glance

	SRT-2104	Resveratrol
Type	Longevity	Longevity
Legal status	Research	OTC
Half-life	15–20 hours	1–3 hours (parent); ~9 hours (total metabolites)
Preferred route	Oral	Oral
Dose frequency	once-daily	once-daily
Beginner dose	250–500 mg	150–250 mg
Intermediate dose	500–1000 mg	250–500 mg
Advanced dose	1000–2000 mg	500–1000 mg
Cycle length	4–12 wks	8–52 wks
Bioavailability	14%	1%
Time to peak	3h	1h
Active duration	24h	9h
Storage	Room temperature, dry, protected from light; capsules stable for shelf life on COA	Room temperature, protected from light; opaque container
PCT required	No	No
Ancillaries required	No	No
Safe for women	Yes	Yes

Verdict

SRT-2104 wins for potent and direct SIRT1 activation, reliability of effect, improved pharmacokinetics, and evidence-backed impact on lipid profiles and inflammation in trials. Mechanistically, SRT-2104 actually activates SIRT1 (downstream of NMN/NR), offering precise, reproducible modulation with far higher bioavailability and selectivity than natural polyphenols.

Resveratrol wins for safety, accessibility, cost, and established long-term tolerability. Its broader array of biological actions (SIRT1, AMPK, mild aromatase inhibition, antioxidant effect) makes it a well-rounded adjunct for stacked protocols. Sourcing is trivial, side effects are minimal, and it is routinely run at low cost across many stacks, though the effects are modest and bioavailability is a major limitation.

Pick A or B?

Pick SRT-2104 if:

A research protocol requires direct, potent SIRT1 activation with documented lipid-lowering and anti-inflammatory effects
The goal is to drive mitochondrial biogenesis or PGC-1α/FOXO pathway modulation in a longevity or metabolic-health context
Stacking with NMN/NR and/or rapamycin for a high-impact, multi-mechanism longevity stack
Managing on-cycle dyslipidemia or chronic inflammation where robust, measurable effect is desired
Preference is for a compound with reproducible pharmacokinetics, clinical-phase data, and minimal CYP interactions

Pick Resveratrol if:

Cost, safety, or ease of sourcing are top priorities for a stack
The protocol emphasizes cardiovascular support, mild antioxidant benefit, or broad-spectrum metabolic health
Looking for mild suppression of aromatase/estrogen signaling as an adjunct to TRT/AAS
Running a protocol where long-term tolerability and low side-effect burden are essential
Pursuing a general low-toxicity, polyphenol-rich lifestyle approach rather than pushing a single metabolic pathway hard

This comparison is presented for informational and educational purposes only. The compounds described may be research chemicals, prescription-only, or regulated substances in your jurisdiction. Consult a qualified medical professional before using any compound. This is not medical advice.